Evidence map›Paper›PMID 41680851›Full record

ArticleBiomarker research2026

T-cell-targeted fusogenic nanovesicles generate CAR-T cells in vivo for rheumatoid arthritis therapy.

Shujie Liang, Keming Lin, Shikun Zhou, Yuncheng Zeng, Yutong Chen, Yiqun Sun, Zhen Xiao, Gui Zhao, Congfei Xu, Peilong Lai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Genes & diseases · 2027
    Review
  2. Review
  3. Nanomaterials Drive In Vivo CAR Immune Cells Engineering.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  4. Review
  5. Frontiers in immunology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shujie Liang *Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510515, P. R. China.
Keming Lin *School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, P. R. China.
Shikun ZhouSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, P. R. China.
Yuncheng ZengSchool of Medicine, South China University of Technology, Guangzhou, 510006, P. R. China.
Yutong ChenSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, P. R. China.
Yiqun SunSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, P. R. China.
Zhen XiaoSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, P. R. China.
Gui ZhaoSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, P. R. China.
Congfei XuSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, P. R. China. xucf@scut.edu.cn.
Peilong LaiDepartment of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510515, P. R. China. lai_peilong@163.com.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2022B1515020025Guangdong Basic and Applied Basic Research Foundation 2024B1515020054National Key Research and Development Program of China 2022YFB3808100National Natural Science Foundation of China 32430059, 52422305, 32271442, 32471434NSFC Incubation Project of Guangdong Provincial People's Hospital KY0120220024 and KY012021160TCL Young Scholar 2024-2027the High-level Hospital Construction Project of Guangdong Provincial People's Hospital DFJHBF202107the National Natural Science Foundation of China 82270161the Science and Technology Planning project of Guangdong Province, China 2023B1111050004
6 · The paper itself

Abstract

backgroundRheumatoid arthritis (RA) is a chronic autoimmune disease in which pathogenic B cells drive persistent inflammation and joint damage. Although CD19-targeted CAR-T cell therapy enables effective B-cell depletion, conventional ex vivo manufacturing and viral vector-based genetic modification limit its scalability and clinical application. Strategies that allow efficient CAR-T cell generation directly in vivo may therefore provide a more practical approach to sustained immune modulation.

methodsWe developed FuNV

resultsFuNV

conclusionsThese findings demonstrate that FuNV

Indexed as

Autoimmune diseaseCAR-T cellMembrane fusionNanovesicleRheumatoid arthritis

Identifiers

PMID41680851
PMCPMC12922314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.